Abstracts tagged "BILAG"

Abstract Number: 607 • 2012 ACR/ARHP Annual Meeting
Activity Index After Renal Failure in a Cohort of 32 Patients with Lupus Nephritis
Cristina Gonzalez-Pulido¹, Sara Croca² and D.A. Isenberg³, ¹Internal Medicine, University Hospital Virgen del Rocio, Seville, Spain, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research, University College London, London, United Kingdom
Background/Purpose: Most published studies that have measured activity in patients with lupus nephritis suggest the disease is relatively quiescent after renal failure. Purpose: To analyze…
Abstract Number: 2621 • 2012 ACR/ARHP Annual Meeting
Sustained Disease Improvement and Safety Profile Over 1745 Patient-Year Experience (7 years) with Belimumab in Systemic Lupus Erythematosus Patients
Joan T. Merrill¹, Richard A. Furie², Daniel J. Wallace³, William Stohl⁴, W. Winn Chatham⁵, Arthur Weinstein⁶, James D. McKay, Ellen M. Ginzler⁸, Z. John Zhong⁹, William W. Freimuth⁹ and Michelle Petri¹⁰, ¹Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²North Shore-LIJ Health System, Lake Success, NY, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Washington Hospital Center, Washington, DC, ⁷Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, ⁸Human Genome Sciences, Inc., Rockville, MD, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: To update belimumab safety and efficacy data over 7 y in patients with active SLE. Methods: 449 SLE patients with SELENA-SLEDAI scores ≥4 were enrolled…
Abstract Number: 1418 • 2012 ACR/ARHP Annual Meeting
Directed Intuitive Assessment of Lupus (the DIAL system for real world clinics) Correlates Well with BILAG and SLEDAI
Anca D. Askanase¹, Katrina M. Shum¹, Stan Kamp², Fredonna C. Carthen², Teresa J. Aberle³ and J.T. Merrill², ¹NYU School of Medicine, New York, NY, ²Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Disease activity measures used in SLE clinical studies, including the SLEDAI (SLE Disease Activity Index) and BILAG (British Isles Lupus Assessment Group) index are…
Abstract Number: 1420 • 2012 ACR/ARHP Annual Meeting
Ethnicity and B Cell Depletion Therapy in Systemic Lupus Erythematosus
A. Lois-Iglesias¹, J. Ishorari² and D.A. Isenberg², ¹Rheumatology, University Hospital Ramón y Cajal, Madrid, Spain. University College London, London, United Kingdom, ²Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose:The aim of this study was to determine if there is any relation between ethnicity and outcome in patients with SLE treated with B cell…
Abstract Number: 614 • 2012 ACR/ARHP Annual Meeting
Predictors of Systemic Lupus Erythematosus Flares: Baseline Disease Activity and Demographic Characteristics From the Combined Placebo Groups in the Phase 3 Belimumab Trials
Ronald F. van Vollenhoven¹, Michelle Petri², Roger A. Levy³, Sandra V. Navarra⁴, Jill P. Buyon⁵, Z. John Zhong⁶, William W. Freimuth⁶ and Ricard Cervera⁷, ¹Karolinska University Hospital, Stockholm, Sweden, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Internal Medicine, Univ Estado Do Rio De Janeiro, Rio de Janeiro, Brazil, ⁴University of Santo Tomas Hospital, Manila, Philippines, ⁵Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁶Human Genome Sciences, Inc., Rockville, MD, ⁷Autoimmune Diseases, Hospital Clínic of Barcelona, Barcelona, Spain
Background/Purpose: Predicting which SLE patients are at increased risk for clinically meaningful flares may be useful in making management decisions. The purpose of this analysis was to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].